Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparin + lidocaine is a combination drug used primarily as an intravesical (bladder) instillation for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Heparin is a glycosaminoglycan with anticoagulant properties that also helps restore the bladder’s mucosal barrier. Lidocaine is a local anesthetic that blocks sodium channels on nerve cells, providing rapid pain relief. When administered together—often in an alkalinized solution to enhance efficacy—the combination provides significant and immediate relief from urinary urgency, frequency, and pain associated with IC/BPS flares. The mechanism involves both anesthetizing bladder nerves (lidocaine) and augmenting the defective permeability barrier of the bladder urothelium (heparin). Clinical studies have shown this combination can provide up to 12 hours of symptom relief[1][2][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin + lidocaine.